Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism
Research output: Contribution to journal › Journal article › Research › peer-review
Rosiglitazone, a thiazolidinedione (TZD), increases insulin sensitivity by reducing levels of plasma NEFA, triglycerides (TG), glucose and serum insulin. Rosiglitazone treatment decreases insulin resistance in type 2 diabetic patients, but no data exist concerning rosiglitazone treatment of patients with syndromes of extreme insulin resistance.
| Original language | English |
|---|---|
| Journal | Journal of Internal Medicine |
| Volume | 250 |
| Issue number | 5 |
| Pages (from-to) | 406-14 |
| Number of pages | 9 |
| ISSN | 0954-6820 |
| Publication status | Published - Nov 2001 |
- Adolescent, Adult, Apolipoproteins B, Body Mass Index, Diabetes Complications, Diabetes Mellitus, Fatty Acids, Nonesterified, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, Insulin Resistance, Male, Mutation, Plasminogen Activator Inhibitor 1, Receptor, Insulin, Thiazoles, Thiazolidinediones, Triglycerides
Research areas
ID: 92192140